Panel Addresses Ezetimibe, PCSK9 Inhibitors for Reducing CV Events
Guideline shifts focus from emphasis on LDL cholesterol targets to individualized approach for lowering overall cardiovascular risk
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.